Elsevier

The Lancet Oncology

Volume 13, Issue 2, February 2012, Pages 115-116
The Lancet Oncology

Comment
VEGF Trap for the treatment of malignant ascites

https://doi.org/10.1016/S1470-2045(11)70394-1Get rights and content

References (8)

There are more references available in the full text version of this article.

Cited by (12)

  • Malignant Ascites: An Overview of Management With Tunneled Peritoneal Drainage Catheters

    2019, Journal of Radiology Nursing
    Citation Excerpt :

    The unabsorbed fluid has a high protein content, resulting in increased vascular permeability and further fluid collection in the peritoneal cavity. When obstruction is severe, the circulating blood volume decreases, activating the renin-angiotensin-aldosterone system and resulting in sodium retention (Becker and Blum, 2012; Becker et al., 2006; Enck, 2012). Increased abdominal fluid from malignant ascites causes increased abdominal pressure.

  • Vascular pathobiology in chronic liver disease and cirrhosis - Current status and future directions

    2014, Journal of Hepatology
    Citation Excerpt :

    Mechanisms by which VEGF inhibition may be beneficial include attenuation of mesenteric angiogenesis and portosystemic collaterals as well as reduction in intrahepatic vascular remodelling and fibrogenesis. Additional effects of VEGF inhibition on reduction in vascular permeability and ascites are also documented [103]. However, further studies are needed in humans and this is being pursued in an indirect manner through analysis of small molecule inhibitors of receptor tyrosine kinases such as sorafenib (with the understanding that these inhibitors target a multitude of receptor tyrosine kinases on different cell types) [10,104].

View all citing articles on Scopus
View full text